Development and Validation of an Anxiety Disorder Prediction Model for Premature Ejaculation Patients
1 other identifier
observational
700
1 country
2
Brief Summary
Background: Premature ejaculation (PE) is a common sexual dysfunction that can significantly impact the quality of life and psychological well-being of affected individuals. Anxiety disorders, often comorbid with PE, exacerbate symptoms and complicate treatment outcomes. There is a critical need for a reliable prediction model to identify patients at risk of developing anxiety disorders associated with PE. Objective: The primary aim of this study is to develop and validate a predictive model that accurately identifies premature ejaculation patients who are at high risk of developing anxiety disorders. The model will be designed to facilitate early intervention strategies and improve patient outcomes. Methods: This prospective observational study will enroll male patients diagnosed with PE from multiple clinical centers. Participants will undergo comprehensive assessments including validated questionnaires, clinical interviews, and medical history reviews to collect baseline data on potential predictors of anxiety disorders. Machine learning algorithms will be utilized to analyze the collected data and derive a predictive model. External validation will be conducted using a separate cohort of patients not involved in the initial model development phase. Outcome Measures: The primary outcome measure will be the accuracy of the predictive model in identifying patients who subsequently develop anxiety disorders within a predefined follow-up period. Secondary outcomes include evaluating the model's sensitivity, specificity, positive predictive value, and negative predictive value. Significance: Successful development and validation of this prediction model could lead to improved patient care through targeted interventions and personalized treatment plans for those at risk of anxiety disorders related to PE. This research may also contribute to a better understanding of the complex interplay between sexual dysfunction and mental health.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Mar 2024
Typical duration for all trials
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 25, 2024
CompletedFirst Submitted
Initial submission to the registry
October 31, 2024
CompletedFirst Posted
Study publicly available on registry
November 7, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 25, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
May 1, 2026
CompletedNovember 7, 2024
October 1, 2024
1 year
October 31, 2024
November 5, 2024
Conditions
Outcome Measures
Primary Outcomes (2)
Anxiety State of patients
Use the Mini International Neuropsychiatric Interview (MINI) to conduct a structured interview with the patient to determine if they have an anxiety disorder.
Within three months after the patient is diagnosed with premature ejaculation.
Accuracy of the Prediction Model
Evaluate the accuracy of the prediction model by comparing its predictions against actual diagnoses of anxiety disorders.
Through study completion, an average fo 1 year
Secondary Outcomes (2)
Sensitivity of the Prediction Model
Through study completion, an average fo 1 year
Specificity of the Prediction Model
Through study completion, an average fo 1 year
Study Arms (2)
Training cohort
This cohort data will be used to screen for independent risk factors for anxiety disorders in patients with premature ejaculation and to initially construct a risk prediction model.
Validation cohort
This cohort data will be used to verify the performance and stability of the risk prediction model to ensure the promotion and use of the model.
Eligibility Criteria
Participants for this study will be male patients diagnosed with premature ejaculation (PE). Sample Size: Approximately 700 patients are expected to be recruited for this study. The sample size was determined based on previous studies and statistical calculations to ensure adequate statistical power. Recruitment Sites: Participants will be recruited from four tertiary hospitals within the country.
You may qualify if:
- Comply with the international medical premature ejaculation diagnostic criteria
- Individuals with a "heterosexual" orientation who engage in vaginal intercourse
- Having a stable relationship with "monogamy"
- The International Index of Erectile Function-5 scale is ≥17 points, indicating that the patient has no erectile dysfunction or only mild erectile dysfunction
- Be informed of the purpose of this study, support this study, and complete the informed consent form
You may not qualify if:
- Minors under the age of 18
- Individuals with a sexual orientation of "gay" or "bisexual"
- The judgment of "ejaculation too fast" is based only on masturbation or non-vaginal sexual intercourse
- The score of the premature ejaculation self-assessment scale is ≤8 points
- Suffering from diseases that may affect anxiety symptoms (hyperthyroidism/hypothyroidism, digestive diseases, malignant tumors, etc.)
- Within 2 months, have taken anti-anxiety drugs and/or drugs for PE treatment
- Those with a history of severe neurological diseases (such as epilepsy) and/or a history of schizophrenia, bipolar disorder, or other mental disorders
- Poor cooperation during diagnostic interviews
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Xijing Hospitallead
Study Sites (2)
Xi'an Daxing Hospital affiliated to Yan'an University
Xi'an, Shaanxi, 710016, China
Xijing Hospital
Xi'an, Shaanxi, 710032, China
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 3 Months
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
October 31, 2024
First Posted
November 7, 2024
Study Start
March 25, 2024
Primary Completion
March 25, 2025
Study Completion
May 1, 2026
Last Updated
November 7, 2024
Record last verified: 2024-10